v3.25.4
Identifiable Intangible Assets, Net and Goodwill (Tables)
 12 Months Ended
Dec. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
 As of December 31, 2025As of December 31, 2024
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, Net		Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Finite-lived intangible assets
Developed technology rights(a)
$100,630 $(70,172)$30,458 $99,397 $(65,044)$34,353 
Brands(b)
1,035 (1,035)— 1,277 (992)285 
Licensing agreements and other
2,341 (1,289)1,052 2,724 (1,513)1,210 
104,006 (72,496)31,510 103,397 (67,549)35,848 
Indefinite-lived intangible assets
IPR&D(c)
21,760 21,760 18,893 18,893 
Licensing agreements and other(d)
460 460 670 670 
22,221 22,221 19,563 19,563 
Identifiable intangible assets
$126,227 $(72,496)$53,731 $122,961 $(67,549)$55,411 
(a)The increase in the gross carrying amount primarily reflect the transfer of $600 million and $590 million from IPR&D to developed technology rights for Padcev and talazoparib (Talzenna), respectively, as well as the impact of foreign exchange, partially offset by impairments of $560 million (see Note 4).
(b)The decrease in the gross carrying amount reflects an impairment of $240 million (see Note 4).
(c)The increase in the gross carrying amount primarily reflects $8.0 billion for the acquisition of Metsera (see Note 2A), partially offset by impairments of $3.9 billion (see Note 4) and the transfers to developed technology rights noted above.
(d)The decrease in the gross carrying amount reflects an impairment of $210 million (see Note 4).
Schedule of Indefinite-Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
 As of December 31, 2025As of December 31, 2024
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, Net		Gross
Carrying
Amount		Accumulated
Amortization
Identifiable
Intangible
Assets, Net
Finite-lived intangible assets
Developed technology rights(a)
$100,630 $(70,172)$30,458 $99,397 $(65,044)$34,353 
Brands(b)
1,035 (1,035)— 1,277 (992)285 
Licensing agreements and other
2,341 (1,289)1,052 2,724 (1,513)1,210 
104,006 (72,496)31,510 103,397 (67,549)35,848 
Indefinite-lived intangible assets
IPR&D(c)
21,760 21,760 18,893 18,893 
Licensing agreements and other(d)
460 460 670 670 
22,221 22,221 19,563 19,563 
Identifiable intangible assets
$126,227 $(72,496)$53,731 $122,961 $(67,549)$55,411 
(a)The increase in the gross carrying amount primarily reflect the transfer of $600 million and $590 million from IPR&D to developed technology rights for Padcev and talazoparib (Talzenna), respectively, as well as the impact of foreign exchange, partially offset by impairments of $560 million (see Note 4).
(b)The decrease in the gross carrying amount reflects an impairment of $240 million (see Note 4).
(c)The increase in the gross carrying amount primarily reflects $8.0 billion for the acquisition of Metsera (see Note 2A), partially offset by impairments of $3.9 billion (see Note 4) and the transfers to developed technology rights noted above.
(d)The decrease in the gross carrying amount reflects an impairment of $210 million (see Note 4).
Schedule of Expected Amortization Expense
The following provides the expected annual amortization expense:
(MILLIONS)20262027202820292030
Amortization expense$4,677 $4,087 $3,723 $2,775 $2,732 
Schedule of Goodwill
The following summarizes the changes in the carrying amount of Goodwill(a):
(MILLIONS)20252024
Balance, beginning
$68,527 $67,783 
Additions(b)
2,163 1,022 
Impact of foreign exchange and other
574 (278)
Balance, ending
$71,264 $68,527 
(a)As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2025 (see Note 17A), our goodwill was reallocated among impacted reporting units. We completed the re-allocation during the first quarter of 2025 and concluded that none of our goodwill was impaired. All goodwill continues to be assigned within the Biopharma reportable segment.
(b)Additions in 2025 primarily represent our acquisition of Metsera and in 2024 primarily represent measurement period adjustments related to our acquisition of Seagen (see Note 2A).